Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADME and pharmacokinetics study of oral [14C]-TNO155 in healthy male participants
NL-OMON51295Active, not recruiting
- Sponsor
- Novartis
- Start
- Feb 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label trial of batoprotafib in cancer (2 arms), sponsored by Novartis. Primary endpoints: Excretion and mass balance of [14C]-radioactivity, Pharmacokinetics of total radioactivity in whole blood and plasma and 1 more. Started Feb 2022; status: active, not recruiting.
02
Drugs
batoprotafib
03
Conditions
cancer
Beyond the preview
Go deeper on NL-OMON51295.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON51295.